Poster Presentation HUPO 2019 - 18th Human Proteome Organization World Congress

Analytical validation of run-to-run and site-to-site performance of a human immune profiling assay and automated data analysis solution for CyTOF mass cytometry technology (#423)

Stephen Li 1 , Daniel Majonis 2 , Vladimer Baranov 1 , Olga Ornatsky 1 , C. Bruce Bagwell 3 , Benjamin C. Hunsberger 3 , Dmitry Bandura 1
  1. Fluidigm Canada Inc., Markham, Ontario, Canada
  2. Fluidigm Corporation, South San Francisco, CA, United States
  3. Verity Software House, Topsham, Maine, USA

Immune profiling is an essential method for quantifying changes in immune population numbers and states over time in health and disease. A cornerstone in translational and clinical research, it is frequently used to investigate chronic inflammation, infectious disease, autoimmune diseases, and cancer. The diversity of immune populations demands a high‑parameter approach to fully and efficiently quantify changes. Mass cytometry, which utilizes CyTOF® technology, is a single-cell analysis platform that has used as many as 50 metal-tagged antibodies1 to resolve discrete cell populations, all in a single tube of sample. It is an ideal solution for routine enumeration of immune cell populations.

We developed a sample-to-answer solution for human immune profiling using mass cytometry: the Maxpar® Direct™ Immune Profiling System. It includes an optimized 30-marker immune profiling panel provided in a single-tube format, validated SOPs for human whole blood and PBMC staining, an instrument data acquisition template, instructions for data acquisition on a Helios™ system, and automated Maxpar Pathsetter™ software for data analysis.

Here we present analytical validation data on repeatability, reproducibility, software precision / accuracy, and site-to-site reproducibility. The repeatability of eight identical donor samples acquired on a single Helios instrument resulted in CVs <12% for whole blood and <9% for PBMC for all major populations (>5% in frequency). Reproducibility of three identical samples acquired on three different Helios instruments resulted in CVs <10% for whole blood and <20% for PBMC for all major populations. We also performed Deming regression to test differences in results obtained by manual gating and Maxpar Pathsetter. For all major populations analyzed, 95% confidence interval of the correlation coefficient contained the value of 1, suggesting no proportional difference between the two methods of analysis. Finally, a multi-site study of whole blood from a single donor stained and analyzed at five institutions independently resulted in CVs of <10% for populations ≥5% in frequency, demonstrating that the Maxpar Direct Immune Profiling System shows a high degree of inter-site reproducibility.

We conclude that this assay provides a robust solution for broad immune profiling using mass cytometry, reducing sources of variability and subjectivity in sample preparation and data analysis.

  1. 1 Simoni, Y., Becht. E., Fehlings, M. et al. “Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.” Nature 557 (2019): 575–579